India’s exports of pharmaceuticals during 2022-23 was valued at $25.4 billion with a growth of almost 3.25 percent over the previous financial year, according to Pharmexcil.
WHO linked the syrups made by India's Maiden Pharmaceuticals to the deaths of 70 children in 2022, though govt stated that subsequent lab tests showed the syrups were not toxic.
The Marion factory in Uttar Pradesh was closed in March, after an analysis last year by Uzbekistan's health ministry of two cough syrups made by Marion, Ambronol and DOK-1 Max.
CDSCO says two cough syrups manufactured by Ankleshwar-based Norris Pharma were found to contain Ethylene Glycol (EG) & Diethylene Glycol (DEG) beyond acceptable limits.
Cough syrups made in India & Indonesia have been linked to deaths of over 300 children globally. Medicines were found to contain high levels of DEG, EG, leading to death.
The medicines either did not contain the claimed volume of ingredients or failed to dissolve quickly enough for absorption by the body, according to the records.
The country put 21 people on trial - 20 of whom are Uzbeks and one Indian - over the deaths last week, making public for the first time a much higher death toll than previously reported.
The batch, manufactured by Fourrts (India) Laboratories Pvt. Ltd for Dabilife Pharma Pvt. Ltd, had high levels of diethylene glycol and ethylene glycol, WHO said.
Naturcold, cough syrup supplied by Riemann Labs, was linked to deaths of 12 kids in Cameroon in March. This is 1st admission by govt of action taken in matter which was flagged by WHO.
Forget comparing it with classics like Hrithik’s Ek Pal Ka Jeena or the slick title track of Dhoom 2, Janaab-e-Aali does not even come close to Ghungroo.
India’s industrial output growth saw a 10-month low in June, with Index of Industrial Production (IIP) growing by mere 1.5% as against 1.9% in May 2025.
Standing up to America is usually not a personal risk for a leader in India. Any suggestions of foreign pressure unites India behind who they see as leading them in that fight.
COMMENTS